Enveric Biosciences (ENVB) said Tuesday it started genotoxicity studies for its primary drug candidate, EB-003, to prepare for an investigational new drug filing.
The laboratory assessments will determine if the compound alters DNA or triggers genetic mutations, the company said.
The evaluations feature standard safety checks to ensure compliance with international health regulations, it said.
Shares of the company were up over 2% in Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.